Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ProQR Therapeutics (PRQR) Income towards Parent Company (2016 - 2025)

ProQR Therapeutics' Income towards Parent Company history spans 5 years, with the latest figure at -$9.1 million for Q4 2025.

  • On a quarterly basis, Income towards Parent Company rose 7.16% to -$9.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$47.6 million, a 56.64% decrease, with the full-year FY2025 number at -$49.1 million, down 65.51% from a year prior.
  • Income towards Parent Company hit -$9.1 million in Q4 2025 for ProQR Therapeutics, up from -$12.9 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for PRQR hit a ceiling of -$2.9 million in Q2 2024 and a floor of -$23.5 million in Q3 2022.
  • Historically, Income towards Parent Company has averaged -$12.4 million across 5 years, with a median of -$11.9 million in 2025.
  • Biggest five-year swings in Income towards Parent Company: skyrocketed 72.01% in 2023 and later crashed 402.18% in 2025.
  • Tracing PRQR's Income towards Parent Company over 5 years: stood at -$20.8 million in 2021, then skyrocketed by 34.92% to -$13.6 million in 2022, then skyrocketed by 60.85% to -$5.3 million in 2023, then plummeted by 85.19% to -$9.8 million in 2024, then rose by 7.16% to -$9.1 million in 2025.
  • Business Quant data shows Income towards Parent Company for PRQR at -$9.1 million in Q4 2025, -$12.9 million in Q3 2025, and -$14.6 million in Q2 2025.